User: Guest  Login
Less Searchfields
Simple search
Title:

[Dupilumab has an additional benefit in treatment of chronic rhinosinusitis with nasal polyps].

Document type:
Review; Journal Article; Meta-Analysis; Review
Author(s):
Klimek, L; Chaker, A; Deitmer, T; Plontke, S K; Wollenberg, B; Bousquet, J; Bachert, C
Abstract:
BACKGROUND: For patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) which cannot be controlled by continuous therapy with intranasal corticosteroids (INCS) and systemic corticosteroids and/or surgical treatment, there were no approved curative options for a long time. For CRSwNP treatment with T2-addressing biologics is possible. On October 24, 2019, the European Commission granted extended approval for dupilumab as the first biological agent for treatment of insufficiently co...     »
Journal title abbreviation:
HNO
Year:
2021
Journal volume:
69
Journal issue:
11
Pages contribution:
868-877
Fulltext / DOI:
doi:10.1007/s00106-021-01018-z
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/33738558
Print-ISSN:
0017-6192
TUM Institution:
Hals-Nasen-Ohrenklinik und Poliklinik
 BibTeX